Compare Citius Pharmaceuticals Inc (CTXR) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Twilio Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Twilio Inc trades at $212.5 (market cap $33.06B). The key difference: Twilio Inc is far larger — about 2258.2× Citius Pharmaceuticals Inc's market cap, and Twilio Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | TWLO | |
|---|---|---|
Market Cap | $14.64M | $33.06B |
Sector | Health | Technology |
52-Week High | $1.82 | $236.64 |
52-Week Low | $0.53 | $92.44 |
Enterprise Value | $10.86M | $31.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Twilio (TWLO) trades at $218.24, up 1.72% today, showing strong momentum after recent earnings beats. The stock is in a bullish technical trend with support at $212 and resistance at $223. Revenue grew to $5.07B in 2025, with net income turning positive at $33.83M, signaling a successful turnaround. Analyst sentiment is overwhelmingly positive, with 77% recommending Buy and a consensus price target of $215.14. Operating cash flow reached $1.0B, reflecting improved financial health.
Outlook: Twilio's AI-driven communication tools and margin expansion under CEO Khozema Shipchandler support growth, but high valuation multiples (P/E 330.67) pose risks. Competition and execution challenges remain key concerns. The stock offers upside if earnings momentum continues, yet volatility near 52-week highs warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
